Who
Martin A. Lehr
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Context Therapeutics.
In numbers
- Trades disclosed
- 30
- Buys
- 12
- Sells
- 0
- Bought
- $280K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 22 Oct 2021
- Last trade
- 19 Feb 2026
- Last filed
- 23 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Feb 2026filed 23 Feb 2026 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —815,000 at $0.00 | filing |
| 19 Feb 2026filed 23 Feb 2026 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —815,000 at $0.00 | filing |
| 9 Jun 2025filed 10 Jun 2025 | CNTX Context TherapeuticsBiotechnology | SEC FORM 4 Bought | $70K100,000 at $0.70 | filing |
| 13 Feb 2025filed 14 Feb 2025 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —802,700 at $0.00 | filing |
| 21 Mar 2024filed 22 Mar 2024 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —291,402 at $0.00 | filing |
| 21 Feb 2023filed 21 Feb 2023 | CNTX Context TherapeuticsBiotechnology | SEC FORM 4 Bought | $4,8915,823 at $0.84 | filing |
| 13 Feb 2023filed 14 Feb 2023 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —287,544 at $0.00 | filing |
| 13 Feb 2023filed 13 Feb 2023 | CNTX Context TherapeuticsBiotechnology | SEC FORM 4 Bought | $4,8775,606 at $0.87 | filing |
| 6 Feb 2023filed 6 Feb 2023 | CNTX Context TherapeuticsBiotechnology | SEC FORM 4 Bought | $4,8895,040 at $0.97 | filing |
| 30 Jan 2023filed 30 Jan 2023 | CNTX Context TherapeuticsBiotechnology | SEC FORM 4 Bought | $4,9197,027 at $0.70 | filing |
| 23 Jan 2023filed 23 Jan 2023 | CNTX Context TherapeuticsBiotechnology | SEC FORM 4 Bought | $4,9246,839 at $0.72 | filing |
| 17 Jan 2023filed 18 Jan 2023 | CNTX Context TherapeuticsBiotechnology | SEC FORM 4 Bought | $5,0196,783 at $0.74 | filing |
| 16 Dec 2022filed 19 Dec 2022 | CNTX Context TherapeuticsBiotechnology | SEC FORM 4 Bought | $15K20,000 at $0.74 | filing |
| 19 Aug 2022filed 22 Aug 2022 | CNTX Context TherapeuticsBiotechnology | SEC FORM 4 Bought | $24K13,000 at $1.85 | filing |
| 25 Feb 2022filed 25 Feb 2022 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —254,300 at $0.00 | filing |
| 16 Dec 2021filed 20 Dec 2021 | CNTX Context TherapeuticsBiotechnology | SEC FORM 4 Bought | $42K13,000 at $3.22 | filing |
| 22 Oct 2021filed 17 Dec 2021 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code O | —52,680 at $0.00 | filing |
| 22 Oct 2021filed 17 Dec 2021 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —210,715 | filing |
| 22 Oct 2021filed 17 Dec 2021 | CNTX Context Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —586,475 | filing |
| 22 Oct 2021filed 17 Dec 2021 | CNTX Context TherapeuticsBiotechnology | SEC FORM 4 Code O | $376K52,680 at $7.14 | filing |
News
No headline names them, or the companies they trade most, lately.